This review proposes that striatal parvalbumin interneurons (PVINs) — early integrators of dopaminergic, inflammatory, and network signals and a principal source of striatal GDNF — undergo a compensatory-to-degenerative shift that promotes maladaptive synaptic plasticity in Parkinson's disease and…

Systematic review and meta-analysis of 13 randomized trials (557 patients) finding apomorphine—especially intermittent subcutaneous injection—significantly improves motor symptoms and reduces OFF time in Parkinson’s disease versus placebo, at the cost of increased mild-to-moderate adverse events.

This review compiles preclinical evidence that the isothiocyanate erucin, a compound from cruciferous vegetables, may protect neurons via antioxidant, anti-inflammatory, and neurotrophic mechanisms and summarizes limited pharmacokinetic and model data with tentative relevance to AD and PD.

This Perspective presents the alpha-synuclein proximity ligation assay (αSYN-PLA) that reveals widespread, non-inclusion oligomeric α-synuclein pathology—including in LB-negative LRRK2 PD—and discusses antibody strategies, structural implications, temporal dynamics, and clinical applications as…

Mechanistic review focusing on how disruptions of the synaptic vesicle trafficking cycle—driven in PD by alpha-synuclein aggregation and LRRK2-Rab trafficking defects—contribute to presynaptic dysfunction and summarizes mechanism-oriented therapeutic strategies.

This review reframes age-related neurodegeneration as driven by heterotypic co-aggregation of amyloidogenic proteins (α-synuclein, tau, Aβ, TDP-43), synthesizing biophysical, cellular, animal, and human data on cross-seeding and shared vulnerability pathways and highlighting translational…

This review synthesizes current knowledge of mitochondria-derived vesicles (MDVs) as a distinct mitochondrial quality control pathway—covering MDV biogenesis, trafficking, clearance, roles in inter-organelle signaling and intercellular communication—and links MDV dysfunction to Parkinson's disease…

Review of technical advances, validation, and clinical application of tau and α-synuclein PET tracers—highlighting second-generation tau tracers (e.g., [18F]PI-2620) and emerging α-synuclein tracer [18F]ACI-12589—that improve differentiation of atypical parkinsonian syndromes.

The authors developed an explainable machine-learning survival model and integer risk score using baseline clinical, autonomic, cognitive and mood measures in de novo PD patients to predict long-term progression of depression (test C-index 0.744) and stratify patients into low/moderate/high risk.

Targeted review of Parkinson's disease–related fatigue that highlights preliminary evidence for rTMS and tDCS reducing fatigue and improving cognitive processing but notes small sample sizes, heterogeneous protocols, and limited standardized outcomes.

The paper reports that DING, a phosphatase found in human brain and derived from St. John's wort, reduces Tau phosphorylation and increases neuronal survival in PC12 cells and correlates with lower phospho‑Tau in a small postmortem human cohort.

The paper presents a high-accuracy (97.4%) deep-learning pipeline—using InceptionGAN augmentation, ConvNeXt and MaxViT feature extractors with Cross-Fusion Attention and hyperparameter optimization (Bayesian + genetic algorithms)—for classifying Alzheimer's and Parkinson's disease from brain MRI…

Small cross-sectional study of 20 Ghanaian PD patients found high rates of malnutrition (≈75%), sarcopenia (45%) and constipation (80%), low caloric/protein intake linked to lower BMI/body fat, thigh circumference inversely correlated with disease duration, and protein intake inversely correlated…

In rotenone and 6-OHDA rat models of Parkinson's, systemic uridine (30 mg/kg for 28 days) reduced peripheral lymphocyte SDH and LDH hyperactivity and serum lipid peroxides, and this effect was abolished by the mitoKATP inhibitor 5-hydroxydecanoate, implicating mitoKATP-mediated mitochondrial…

Multimodal imaging of >300 PD-spectrum participants reveals stage-dependent corticostriatal reorganization: early hyperconnectivity between the posterior caudate and primary motor cortex peaking around ~50% putaminal dopamine loss, and progressive loss of posterior putamen–posterior cortical…

Multicenter study of 108 idiopathic RBD patients found 40% discordance between striatal dopaminergic imaging and quantitative motor testing, with a motor-slowing/DAT-normal subgroup showing worse cognition and autonomic dysfunction, suggesting a more diffuse progression pattern.

Case report plus systematic review (19 patients) describing SEZ6L2 autoimmunity as a rare cause of subacute cerebellar ataxia frequently accompanied by cognitive dysfunction and parkinsonism, with ~47% showing partial improvement after immunotherapy.

A broad, up-to-date review positioning glycolysis and cell type–specific metabolic reprogramming as a central pathological axis across neurodegenerative diseases and summarizing actionable targets (e.g., PFKFB3, ANLS, microglial glycolysis), multimodal measurement methods, and therapeutic…

Postmortem analysis reveals alpha-synuclein inclusions in cerebellar oligodendrocytes, concurrent myelin rarefaction, and hypertrophy of dentate nucleus neurons in idiopathic Parkinson’s disease.

Using human iPSC-derived microglia, the study shows IFNγ reprograms microglial metabolism and lipidome toward a resolving-like phenotype that partially counteracts α-synuclein PFF-driven harmful secretome effects on human dopaminergic neurons.

Perspective proposing that hepatic stress—through bile acid–driven dysbiosis and mitochondrial antigen presentation—may expose mitochondrial antigens and elicit autoimmune responses that contribute to Parkinson's disease initiation and progression.

A narrative review linking endocannabinoid system modulation to regulation of nitrosative stress and neuroinflammation, arguing that cannabinoid-based interventions may slow progression in neurodegenerative diseases including Parkinson's disease.

This study finds significant enrichment of likely pathogenic VPS13C variants in idiopathic REM sleep behavior disorder (iRBD), especially the iRBD-first α-synucleinopathy subtype, and links carriers to worse RBD symptoms, autonomic and REM EEG abnormalities, and faster conversion to overt…

Real-world, open-label multicentre study of 50 advanced PD patients found subcutaneous foslevodopa/foscarbidopa infusion significantly improved motor function (UPDRS III), sleep and PDQ-8 quality-of-life scores with low dropout over 6–12 months across White and non-White cohorts.

A prospective cohort of Gaucher disease patients (22 baseline, 18 followed ~37 months) shows progressive subtle parkinsonism, increased non-motor symptoms including sleep disturbances, declining memory performance, high prevalence/progression of sensorineural hearing loss, and frequent multifocal…